{
  "abstract": "Background B cells are key players in several autoimmune diseases, contributing to disease pathogenesis through autoantibody production, T cell activation, and cytokine secretion. Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS) are closely associated with B cell dysregulation. Recently, B cell-targeted therapies have emerged as promising treatments for these conditions. T cell engagers (TCEs) provide a more direct and robust mechanism for targeting B cells with reduced side effects, improved tissue penetration, making them a promising approach in the treatment of multiple autoimmune diseases.Methods EAE was induced in hCD3/hCD19/hCD20 mice to establish a robust disease model. Mice were then treated with either monoclonal antibodies targeting CD19/CD20 or TCEs designed to specifically target B cells. Clinical symptom scores, histopathological changes in the central nervous system, and immune cell subset dynamics were assessed to evaluate the efficacy and safety of the two therapeutic approaches. Additionally, serum cytokine levels and B cell surface marker expression were measured to elucidate the underlying mechanisms of action.Results TCE treatment demonstrated superior efficacy in reducing clinical symptoms and pathological demyelination in EAE mice compared to other therapies. TCEs effectively depleted B cells, inhibited autoantibody production, and restored immune cell balance. Moreover, TCE-treated mice exhibited fewer side effects and better overall safety profiles.Conclusions TCEs represent a promising novel B cell-targeted therapy for autoimmune diseases, showing enhanced efficacy and safety in mouse EAE model. This study provides valuable insights into the potential of TCEs as a new therapeutic strategy for B cell-mediated autoimmune diseases.",
  "authors": [
    {
      "affiliations": [
        "WXi ApTec, Shanghai, Shanghai, China"
      ],
      "name": "Mengwen Huang"
    },
    {
      "affiliations": [
        "WXi ApTec, Shanghai, Shanghai, China"
      ],
      "name": "Fugang Li"
    }
  ],
  "title": "729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis",
  "uid": "0e764384-e074-53bb-a4ed-b33a0a676854"
}